Screener
Protagonist Therapeutics PTGX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $213.48M+3,749% | $56.37M+99.0% | $7.44M-95.6% | $4.71M+0.8% | $5.55M+33.1% | ||
| $42.06M+13.6% | $46.74M+30.2% | $46.36M+32.8% | $40M+11.2% | $37.04M+10.5% | ||
| $12.65M+19.9% | $13.28M+13.1% | $11.43M+27.7% | $11.13M+9.6% | $10.55M+11.8% | ||
| $54.71M+15.0% | $60.02M+26.0% | $57.79M+31.8% | $51.13M+10.9% | $47.59M+10.8% | ||
| $158.77M+478% | -$3.65M+81.1% | -$50.36M-140% | -$46.42M-12.0% | -$42.04M-8.4% | ||
| 74.4%+832pp | -6.5%+61.7pp | -677.1%-751pp | -985.2%-98.5pp | -758%+173pp | ||
| -$81K-325% | $53K-35.4% | —— | $33K-76.6% | $36K-62.9% | ||
| $165.11M+577% | $2.28M+120% | -$43.72M-133% | -$39.34M-17.0% | -$34.6M-10.6% | ||
| $2.27M+1,217% | -$1.5M— | $666K-66.5% | $0+100% | $172K+125% | ||
| $162.85M+568% | $3.78M+132% | -$44.38M-134% | -$39.34M-18.5% | -$34.77M-13.6% | ||
| 76.3%+703pp | 6.7%+47.9pp | -596.8%-674pp | -834.9%-124pp | -627%+108pp | ||
| $2.29+516% | $0.05+126% | -$0.70-135% | -$0.62-14.8% | -$0.55-10.0% | ||
| $159.16M+481% | -$3.24M+83.0% | -$49.98M-139% | -$46.06M-11.7% | -$41.74M-8.3% | ||
| 74.6%+827pp | -5.7%+61.6pp | -672%-746pp | -977.5%-95.8pp | -752.6%+173pp | ||
| $158.77M+478% | -$3.65M+81.1% | -$50.36M-140% | -$46.42M-12.0% | -$42.04M-8.4% |
FAQ
- What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics (PTGX) generated $282.0M in revenue over the trailing twelve months, up 34.8% year over year.
- Is Protagonist Therapeutics profitable?
- Protagonist Therapeutics reported $82.9M in net income over the trailing twelve months, a 29.4% net margin.
- What is Protagonist Therapeutics's earnings per share?
- Protagonist Therapeutics's diluted EPS over the trailing twelve months is $1.02.
- Where does Protagonist Therapeutics's income statement data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
